1.10.15 Liver cell therapy can reduce incidence and severity of hyperammonemic crises in infants with urea cycle disorders
Cytonet presents current study findings on the occasion of the annual meeting of the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2015
11.8.14 First baby patient in Canada to receive liver cell therapy
A three-months old girl became the first patient in Canada to receive liver cell therapy, an experimental and potentially life-saving procedure from Cytonet LLC, to improve the function of her liver until she was old enough to receive a liver transplant. Under the care of Dr. Aneal Khan, assistant Professor of Medical Genetics and Pediatrics at Alberta Children’s Hospital, University of Calgary, the patient received liver cell therapy in November 2012 and a liver transplant in April 2014. The girl’s journey has been widely chronicled in the media, by outlets such as the Calgary Herald, the University of Calgary’s UToday, and the Canada Press.
14.3.14 FIRST DATA ON CYONET’S LIVER CELL THERAPY FOR UREA CYCLE DISORDERS PRESENTED AT THE ANNUAL MEETING OF THE SOCIETY FOR INHERITED METABOLIC DISORDERS (SIMD)
Weinheim, Germany and Raleigh-Durham, NC, March 10, 2014 – Interim data on the use of liver cell therapy (LCT) for the treatment of pediatric patients with Urea Cycle Disorders (UCD) were presented today at the Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) in Pacific Grove, California. Read on...
16.1.14 CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN
Weinheim/Germany, January, 2014 – International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its liver cell therapy for the treatment of Urea Cycle Disorders (UCD) in children.
UCD is a life-threatening liver metabolism disorder which can affect newborns and infants, causing toxic levels of ammonia to accumulate in the body. This can lead to massive damage of the brain and nervous system. Cytonet’s liver cell therapy has the potential to stabilize ammonia levels through infusion of healthy liver cells, potentially increasing the length of time children can safely wait until they can undergo a liver transplant. Read on...
25.8.13 Liver cell therapy: Urea cycle defects – CCD clinical trial program
In December 2013, Cytonet cleared a further vital hurdle – it submitted liver cell therapy for the treatment of congenital urea cycle defects to the European Medicines Agency EMA for regulatory approval. In the August 2013 issue of our newsletter, there is a concise summary of the very rare metabolic disorder of the liver „congenital urea cycle defects”, as well as information on the CCD clinical trial program in Europe and North America to study liver cell therapy in newborns and children up to 5 years of age. For more information please look here: Cytonet Newsletter August 2013
6.8.12 Cure the Cycle Challenge
The Cure the Cycle Challenge is an annual event, comprising a full day bike ride through Napa Valley. Participants in the Challenge raise money and awareness for Urea Cycle Disorders. The event was created by the National Urea Cycle Disorders Foundation (NUCDF) and a link to the event site can be found here http://curethecycle.dojiggy.com/. Read on...
29.2.12 Cytonet Recognizes Rare Disease Day with Efforts to Help Ensure – UCD Diagnoses Are Not Missed
Heidelberg/Germany, February 27, 2012 – For parents of babies born with urea cycle disorders (UCD), the joy of giving birth to a perfect baby can quickly turn to devastation as the baby’s health rapidly declines, going from symptoms such as being tired and irritable, to not eating, to experiencing seizures and coma. UCDs are congenital and often life-threatening disorders of ammonia metabolism in the liver that cause neurotoxic ammonia to accumulate in the body, potentially leading to massive damage of the nerves and the brain and death. Read on...
14.2.12 Cytonet Trials Aim to Better Assess Severity of Urea Cycle Disorders – Using New Assay for Urea Production
Heidelberg/Germany, February 2012 – International biotechnology firm Cytonet has launched a new clinical trial in Germany to compare the urea cycle activity of pediatric patients suffering from urea cycle disorders (UCD) to normal healthy children using an innovative assay to measure urea production. Researchers hope to provide a diagnostic tool to predict the severity of the urea cycle defect. Read on...